Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report

Figure 1 Magnetic resonance imaging images of the primary Merkel cell carcinoma lesion. A: Baseline; B: After two cycles of chemotherapy (partial response); C: After six cycles of chemotherapy (progression of the disease); D: After seven cycles of avelumab (partial response); E: After 14 cycles of avelumab (partial response); F: After 28 cycles of avelumab.

Figure 2 Photographic registries of the evolution of the primary Merkel cell carcinoma lesion. A: Baseline avelumab; B: After two cycles of avelumab; C: After seven cycles of avelumab; D: After 16 cycles of avelumab; E: After surgery, radiotherapy, and 28 cycles of avelumab; F: Follow-up, more than 2.5 years after surgery.